Search results
Results from the WOW.Com Content Network
Chronic myeloid leukemia treatments include tyrosine kinase inhibitors, high-dose therapy with allogeneic transplant, and other medications. Get detailed information about chronic myeloid leukemia (CML) treatment options in this summary for clinicians.
Chronic myelogenous leukemia treatment may include targeted therapy, immunotherapy, chemotherapy, stem cell transplant, donor lymphocyte infusion, and/or surgery. Learn more about the diagnosis and treatment of CML in this expert-reviewed summary.
Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.
Guidelines Treatment by Cancer Type Detection, ... - Chronic Myeloid Leukemia. Evidence Blocks. ... Guidelines for Patients. Chronic Myeloid Leukemia-English Version 2023. International. Harmonized. English (Africa) Version 1.2023. Disclosures. Disclosure Policy. Panel Member Disclosures.
Treatment options for people with chronic myeloid leukemia (CML) depend on the phase of their disease (chronic, accelerated, or blast phase), their age, other prognostic factors, and the availability of a stem cell donor with matching tissue type.
These NCCN Guidelines for Patients are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia, Version 1.2023 – August 5, 2022. View the NCCN Guidelines for Patients free online. NCCN.org/patientguidelines. Find an NCCN Cancer Center near you. NCCN.org/cancercenters. Connect with us.
CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase–CML.
Frontline therapy: Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib are approved by the United States Food and Drug Administration for first-line treatment of newly diagnosed CML in chronic phase (CML-CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses but had ...
Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.
151 Altmetric. Metrics. Abstract. The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years.